March 18, 2020 Off

Oxford Biomedica, Juno Therapeutics in LentiVector deal

By Dino Mustafić

Oxford Biomedica has signed a new Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s company, Juno Therapeutics to use Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programmes in oncology and other indications.

March 17, 2020 Off

NANOBIOTIX 2019 Annual Results

By BusinessWire

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN: FR0011341205 – the ‘‘Company’’), a late clinical-stage…